EXECUTIVE TEAM

CEO

• Chas has over 30 years’ experience in the medical device industry and has founded, led and sold successful medical device start-up companies since 1996.
• Prior to this, Chas worked for CR Bard for twelve years in various sales, marketing and general management roles. During this time he was based in the USA for eight years in senior positions including Vice-President for Bard Cardiovascular. After leaving Bard, Chas co-founded embolic filter and carotid stent specialists MedNova which was acquired by Abbott in 2005. He then co-founded Novate Medical which designed and developed the Sentry IVC filter which was sold to BTG in 2019 and at the same time became CEO of Veryan Medical. He steered the company through design, development, commercialisation and finally to acquisition by Otsuka Medical Devices in 2018.

Chief Financial Officer

• Experience across a range of industries including Energy, Pharma and Medical Devices.
• Has held senior finance roles in both start up and blue chip listed multinational companies.
• Responsible for all aspects of the company’s finance function including accounting, financial strategy, planning, analysis, tax and treasury.

Chief Medical Advisor

• Dr. Wiechmann has been in private practice for 26 years with Vascular & Interventional Physicians in Gainesville, Florida, USA, with a particular interest in peripheral arterial disease & critical limb ischemia, abdominal aortic aneurysms, carotid intervention, and venous disease.
• He has been elected a Fellow in 4 different medical associations, including the Society of Interventional Radiology, the Society of Vascular Medicine, the American Heart Association, and the Outpatient Endovascular & Interventional Society (OEIS) and has served in many leadership roles in these societies.
• Dr. Wiechmann is a founding member of the Outpatient Endovascular & Interventional Society (OEIS), serves on the Board, and is immediate past-President of OEIS. He has given over 230 invited lectures, has been principal investigator in numerous clinical trials in peripheral arterial intervention, carotid stenting, medical therapy for PAD, and stem cell therapy for critical limb ischemia, and is lead or co-author on 30 peer-reviewed articles.

VP, R&D and Technical Operations

• 25-years work in research and development of medical devices.
• Morgan has been actively engaged in driving product innovation across various clinical areas and has led the development of solutions from concept to commercialisation.
• With a background in Polymer Technology Morgan has been an Inventor on several patented technologies including hydrophilic device coatings, orthopaedic braces, urology catheters, emergency vascular access tools and vascular interventional devices.
• Proficiency in people leadership skills, strategic thinking, project management, and problem-solving

Technology/Business Advisor

• A Medical Device entrepreneur. Raised >€150 million of VC and Corporate funds in UK, US, EU and Ireland. He is currently CTO at Veryan Medical, an Imperial College spinout acquired by Otsuka in 2018, developing next generation SFA stenting products.
• In addition, Paul co-founded Novate Medical, was CEO initially, then CSO. Novate developed an innovative IVC Filter which was FDA 510k cleared and CE marked. The Company was acquired in 2018 by BTG and in turn by BSCI in 2019.
• Previously, he was a co-founder and General Manager of MedNova and was responsible for the development of novel stroke treatment technologies. The Company was acquired by Abbott Laboratories in 2007.
• More recently, he was Chairman of Embo Medical a spinout from the NUIG/Stanford Bio-Innovate Program which was acquired by C.R. BARD in 2015.
• Paul has invested in several Medtech startups including a number of BioInnovate spinout companies. and holds Board positions with Proverum Medical, KITE Medical, Bluedrop Medical, Selio Medical, InVera Medical and Ostoform.
• Prior to his experience in start-up companies he held several senior roles in Operations, Product Development and R&D. He was Director of R&D for Bard Cardiology where he led the development of numerous cardiovascular devices. Paul has extensive experience in licensing and IP portfolio management and is the holder of more than 60 US patents for bio-materials, surgical and cardiovascular products.
• Paul has been appointed Adjunct Professor in the School of Science and Engineering at the University of Galway.

Director of Sales & Marketing- International

• 30 years’ experience in the medical device industry
• Previously held sales positions in Autosuture (United States Surgical) and Schneider; senior marketing positions in Biomedical Sensors (a Pfizer Hospital Product Group company), MedNova and Novate
• Veryan Global Marketing Director from bench to bedside

HR & Corporate Services Director

• Over 15 years of human resources experience across a range of sectors, including Medical Devices, Biotechnology, Non-Profits, and Technology.
• Extensive global experience working at both strategic and operational levels.
• Professional in Human Resources (PHR) certified through HRCI, a US professional body for HR practitioners.

Chief Commercial Officer

• 30 years’ experience leading commercial teams in the medical device industry in the US, Europe, Asia and Latin America.
• Joe started his sales and sales leadership career with Bausch & Lomb Corporation.  He then joined CR Bard’s Peripheral Vascular Division.  While at CR Bard he held numerous positions, culminating in the role of Vice President of US Sales.
• Joe then joined Endologix as Vice President of US Sales and was promoted to Vice President of Global Sales.

VP Scientific Affairs

• More than 25 years’ experience in the medical device industry.
• Previously worked in international clinical and medical affairs positions with Olympus Diagnostics, Abbott Diagnostics and Biotronik AG.
• Prior to joining Veryan, she was the Director Medical Affairs at Biotronik AG and was responsible for the global clinical study program for interventional cardiology and structural heart and supported the global approval of their drug eluting stent, drug coated balloon, covered stent and resorbable scaffold.